Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 2004

View Archived Issues

LEA-29Y superior to ciclosporin in renal transplantation

MR tacrolimus can replace standard tacrolimus in liver transplantation

Visilizumab found effective in refractory ulcerative colitis

BPC-157 reported to promote ulcer healing in rats

Renzapride improves bowel function and reduces abdominal pain/discomfort in IBS

Novartis reports Q1 regulatory and clinical highlights

R&D projects proceeding as planned at Actelion

European orphan drug status for HuMax-CD4 in CTCL

Progress of dopamine D1-selective antagonist lines up milestones for CeNeS

IND cleared for phase I trials of GI-4000 series

Nine-month results from TAXUS VI study

Positive phase I/II results for CZEN-002 in vulvovaginal candidiasis

Vertex expands discovery and development collaboration with CFFT

Basilea to advance BAL-5788 into phase III

Treatment commences in phase I trial of ATN-224 in solid tumors

sNDA filed for once-monthly oral formulation of Boniva

Pivanex enters new phase II studies in CLL and malignant melanoma

Xifaxan approved for travelers' diarrhea caused by noninvasive E. coli

WX-UK1 enters phase I trial at Fox Chase

Intercell signs license agreement with Merck & Co.

Insulin formulation allows absorption through the gastrointestinal tract

Pioglitazone improves features of nonalcoholic steatohepatitis

Aliskiren reported as safe and effective as irbesartan for mild to moderate hypertension

Cardiovascular benefits of pravastatin in type 2 diabetics

Monoclonal antibodies against truncated Abeta peptides and their use as diagnostics for AD

Allergan presents new prostaglandin analogues with utility as ocular hypotensive agents

New analgesic vanilloid VR1 antagonists emerge from Novartis R&D

GSK researchers identify chemokine CCR8 receptor antagonists for use in asthma therapy

Novel retinoid RXR partial agonists claimed as antidiabetic agents by Allergan

New cathepsin K inhibitors developed at Merck Frosst

Nissan Chemical scientists design new TPO receptor agonists

Novel respiratory syncytial virus inhibitor from Arrow Therapeutics

Small molecule broad spectrum anti-herpes simplex virus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...